Teriflunomide Tablet, Film Coated
NDC Package 0480-3157-56
Package Information
Teriflunomide tablets is a medication used to treat multiple sclerosis-MS. This formulation utilizes a tablet, film coated delivery system. Marketed by Teva Pharmaceuticals, Inc., this product is identified by NDC 0480-3157 and is authorized under FDA application ANDA209700.
Identification & Billing
- RxCUI: 1310525 - teriflunomide 14 MG Oral Tablet
- RxCUI: 1310533 - teriflunomide 7 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0480 - Teva Pharmaceuticals, Inc.
- 0480-3157 - Teriflunomide
- 0480-3157-56 - 30 TABLET, FILM COATED in 1 BOTTLE
- 0480-3157 - Teriflunomide
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0480-3157-56 identifies a specific commercial package of 30 tablet, film coated in 1 bottle of Teriflunomide, a human prescription drug labeled by Teva Pharmaceuticals, Inc.. This tablet, film coated is formulated for oral use and contains teriflunomide as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Teva Pharmaceuticals, Inc. on March 13, 2023. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat multiple sclerosis-MS. It is not a cure for MS but is thought to work by decreasing certain immune system cells (lymphocytes) which can attack the nerves in your brain and spinal cord. This helps decrease the number of flare-ups (relapses) and may help slow down physical problems caused by MS.
How is this Teva Pharmaceuticals, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00480315756. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.